Just came across something interesting about how the really big money is positioned right now. Chase Coleman, this billionaire hedge fund manager, has basically concentrated 68% of his $24.5 billion fund into just 10 stocks. That's a pretty bold move, and honestly, it tells you something about where smart money is looking.

So who is Chase Coleman and why should we care? The guy's managing Tiger Global Management, overseeing $46 billion total in assets. His personal net worth sits around $6 billion, which put him at 581 on the Forbes billionaire list. But what's more interesting than his net worth is how he's actually deploying capital.

His top holdings are basically the obvious mega-cap plays. Meta's at 16.5% of the portfolio, Microsoft at 8.5%, then Apollo Global Management, Alphabet, Sea Limited, Amazon, Nvidia, Take-Two Interactive, Eli Lilly, and Flutter Entertainment rounding out the top 10. Nearly half of these are from the "Magnificent Seven" crowd - Meta, Microsoft, Alphabet, Amazon, Nvidia. You know, the stocks everyone's been talking about.

What caught my attention is how all of these are large-cap names. Even the smallest one, Take-Two Interactive, has a market cap pushing $40 billion. There's zero small-cap speculation here. It's pure institutional-grade holdings.

Looking at the specifics, Meta's got 3.43 billion daily active users across Facebook, Instagram, Messenger, and WhatsApp. That's an insane moat for advertising. Plus Zuckerberg's been talking about smart glasses becoming the next computing platform. Over a billion people wear glasses globally, and the idea that these become AI glasses in the next 5-10 years is actually compelling when you think about it long-term.

Alphabet and Nvidia have both caught some heat recently - antitrust issues for Google, China trade restrictions hammering Nvidia's GPU sales - but Coleman's clearly not spooked. I'd bet both do better than the market's currently pricing in.

Eli Lilly's interesting too. Yeah, earnings have been spotty, and there's Trump tariff uncertainty, but they've basically locked down 50% of the GLP-1 market. Mounjaro and Zepbound are selling like crazy. They're filing for an oral weight-loss pill later this year, and Verzenio is printing money in oncology. That's real revenue, not speculation.

If I had to pick the best of Coleman's bunch though, I'd go with Amazon. Every time Amazon's had a real pullback historically, it's been a gift for long-term holders. This one probably isn't different. Sure, tariffs could be a headwind, but AWS has a decade-plus runway with AI, e-commerce still has room to grow, and healthcare, satellite internet, and autonomous vehicles are all potential moonshots. Coleman's fund was sitting on $1.4 billion of Amazon at year-end 2024.

The fact that Chase Coleman - someone managing this much capital - is this concentrated in mega-cap tech and healthcare plays tells you where institutional money thinks the real opportunities are. Whether you're looking at his net worth or his actual portfolio moves, the message is pretty clear about where conviction lies in this market.